Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro
Open Access
- 23 August 2010
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 161 (2), 393-404
- https://doi.org/10.1111/j.1476-5381.2010.00881.x
Abstract
BACKGROUND AND PURPOSE The conversion of clopidogrel to its active metabolite, R-130964, is a two-step cytochrome P450 (CYP)-dependent process. The current investigations were performed to characterize in vitro the effects of different CYP inhibitors on the biotransformation and on the antiplatelet effect of clopidogrel. EXPERIMENTAL APPROACH Clopidogrel biotransformation was studied using human liver microsomes (HLM) or specific CYPs and platelet aggregation using human platelets activated with ADP. KEY RESULTS Experiments using HLM or specific CYPs (3A4, 2C19) revealed that at clopidogrel concentrations >10 µM, CYP3A4 was primarily responsible for clopidogrel biotransformation. At a clopidogrel concentration of 40 µM, ketoconazole showed the strongest inhibitory effect on clopidogrel biotransformation and clopidogrel-associated inhibition of platelet aggregation with IC50 values of 0.03 ± 0.07 µM and 0.55 ± 0.06 µM respectively. Clarithromycin, another CYP3A4 inhibitor, impaired clopidogrel biotransformation and antiplatelet activity almost as effectively as ketoconazole. The CYP3A4 substrates atorvastatin and simvastatin both inhibited clopidogrel biotransformation and antiplatelet activity, less potently than ketoconazole. In contrast, pravastatin showed no inhibitory effect. As clopidogrel itself inhibited CYP2C19 at concentrations >10 µM, the CYP2C19 inhibitor lansozprazole affected clopidogrel biotransformation only at clopidogrel concentrations ≤10 µM. The carboxylate metabolite of clopidogrel was not a CYP substrate and did not affect platelet aggregation. CONCLUSIONS AND IMPLICATIONS At clopidogrel concentrations >10 µM, CYP3A4 is mainly responsible for clopidogrel biotransformation, whereas CYP2C19 contributes only at clopidogrel concentrations ≤10 µM. CYP2C19 inhibition by clopidogrel at concentrations >10 µM may explain the conflicting results between in vitro and in vivo investigations regarding drug interactions with clopidogrel.Keywords
This publication has 44 references indexed in Scilit:
- Guide to Receptors and Channels (GRAC), 4th editionBritish Journal of Pharmacology, 2009
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active MetaboliteDrug Metabolism and Disposition, 2009
- Predictors of Heightened Platelet Reactivity Despite Dual-Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary InterventionThe American Journal of Cardiology, 2009
- A population-based study of the drug interaction between proton pump inhibitors and clopidogrelCMAJ : Canadian Medical Association Journal, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- In vitro Inhibition of CYP1A2 by Model Inhibitors, Anti‐Inflammatory Analgesics and Female Sex Steroids: Predictability of in vivo InteractionsBasic & Clinical Pharmacology & Toxicology, 2008
- Prevalence of Potentially Severe Drug-Drug Interactions in Ambulatory Patients with Dyslipidaemia Receiving HMG-CoA Reductase Inhibitor TherapyDrug Safety, 2005
- The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart diseaseThrombosis and Haemostasis, 2005
- Pharmacokinetics of clopidogrel after administration of a high loading doseThrombosis and Haemostasis, 2004